Risk of cardiovascular adverse events from trastuzumab (Herceptin ®) in elderly persons with breast cancer: A population-based study

Breast Cancer Research and Treatment

Volumn 144, Issue 1, 2014, Pages 163-170

  Tsai, H T ^a   Isaacs, C ^a   Fu, A Z ^a   Warren, J L ^b   Freedman, A N ^b   Barac, A ^c   Huang, C Y ^d   Potosky, A L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adverse event; Breast cancer; Cardiomyopathy; Heart failure; Risk; Trastuzumab

Indexed keywords

TRASTUZUMAB;

AGE; AGED; ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER STAGING; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; GERIATRIC PATIENT; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HEART DISEASES; HUMANS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEER PROGRAM;

EID: 84894648709     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2836-7     Document Type: Article

References (20)

1. Curigliano G, Mayer EL, Burstein HJ et al (2010) Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis 53:94-104
2. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265-4274
3. Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244
4. Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792-3799
5. Bowles EJ, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293-1305
6. Warren JL, Klabunde CN, Schrag D et al (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:3-18
7. Klabunde CN, Potosky AL, Legler JM et al (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267
8. Kurth T, Walker AM, Glynn RJ et al (2006) Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163:262-270
9. Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763
10. Chen T, Xu T, Li Y et al (2011) Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev 37:312-320
11. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382:1021-1028
12. Serrano C, Cortes J, De Mattos-Arruda L et al (2012) Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 23:897-902
13. Sengupta PP, Northfelt DW, Gentile F et al (2008) Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc 83:197-203
14. Geisberg C, Pentassuglia L, Sawyer DB (2012) Cardiac side effects of anticancer treatments: new mechanistic insights. Curr Heart Fail Rep 9:211-218
15. Cote GM, Sawyer DB, Chabner BA (2012) ERBB2 inhibition and heart failure. N Engl J Med 367:2150-2153
16. Tarantini L, Cioffi G, Gori S et al (2012) Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 18:113-119
17. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332-344
18. Sliwkowski MX, Lofgren JA, Lewis GD et al (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26:60-70
19. Keefe DL (2002) Trastuzumab-associated cardiotoxicity. Cancer 95:1592-1600
20. Birman-Deych E, Waterman AD, Yan Y et al (2005) Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. MedCare 43:480-485